Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer – the SENTRY clinical trial
Klinicka onkologie · 2024
DOI: 10.48095/ccko2024126 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Klinicka onkologie, 2024. Verfasst von P Sorokin und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Sentinel Lymph Node Biopsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: While total hysterectomy and bilateral salpingo-oophorectomy without lymph node staging are standard for low- and intermediate-risk endometrial cancer, certain histopathologic factors revealed after surgery can necessitate additional interventions. Our study assessed the influence of sentinel lymph node biopsy on postoperative decision-making. MATERIALS AND METHODS: In the SENTRY trial (July 2021 - February 2023), we enrolled patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IA-IB low-grade endometrioid endometrial cancer. Laparoscopic sentinel lymph node mapping using indocyanine green was performed alongside total hysterectomy with bilateral salpingo-oophorectomy. Subsequent management changes based on sentinel lymph node biopsy results were evaluated. The trial was registered at ClinicalTrials.gov (NCT04972682). RESULTS: Of the 100 enrolled participants, a bilateral detection rate of 91% was observed with a median detection time of 10 min (interquartile range 8-13 min). Sentinel lymph node metastases were found in 8% (N = 8) of participants. Postoperative FIGO staging increased in 15% (N = 15) and decreased in 5% (N = 5) of patients. Sentinel lymph node biopsy results altered the adjuvant treatment plan for 20% (N = 20): external beam radiotherapy was omitted in 12% (N = 12) while 6% (N = 6) had external beam radiotherapy +/- systemic chemotherapy added due to sentinel lymph node metastases. In 2% (N = 2), the external beam radiotherapy field was expanded with the paraaortic region. No intraoperative complications were reported and no 30-day major morbidity and mortality occurred. Throughout a median follow-up of 14 (95% CI 12-15 months, neither patient-reported lymphedema nor pelvic recurrence surfaced in the cohort. CONCLUSIONS: Sentinel lymph node biopsy using indocyanine green is a safe procedure and allows tailoring adjuvant therapy in presumed low- and intermediate-risk endometrial cancer. It assists in avoiding external beam radiotherapy overtreatment and introducing additional modalities when necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Sorokin, P., Novozhilov, M., Utkin, D., Abduragimova, Z., Dudina, I., Nikiforchin, A., & Kulikova, S. (2024). Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer – the SENTRY clinical trial. Klinicka onkologie. https://doi.org/10.48095/ccko2024126
Vancouver
Sorokin P, Novozhilov M, Utkin D, Abduragimova Z, Dudina I, Nikiforchin A, et al. Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer – the SENTRY clinical trial. Klinicka onkologie. 2024. doi:10.48095/ccko2024126
BibTeX
@article{Sorokin2024,
author = {Sorokin, P and Novozhilov, M and Utkin, D and Abduragimova, Z and Dudina, I and Nikiforchin, A and Kulikova, S},
title = {Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer – the SENTRY clinical trial},
journal = {Klinicka onkologie},
year = {2024},
doi = {10.48095/ccko2024126}
}
EUVIMED